First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval
| العنوان: | First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval |
|---|---|
| المؤلفون: | Lai Wei, Claire F. Verschraegen, Hallie Barr, Cassandra Grenade, Chadwick Wright, Akram Hussein, Andrew C. Brown, Ye Zhou, Songzhu Zhao, Rochelle Batdorf, Dramane Konate, Ashima Goyal, Bhavana Konda, Manisha H. Shah, Mona Natwa, Sherise C. Rogers, Bonnie Williams |
| المصدر: | Journal of Clinical Oncology. 37:e15691-e15691 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Peptide receptor, business.industry, Medical record, Neuroendocrine tumors, medicine.disease, Internal medicine, Radionuclide therapy, Medicine, business, Real world data |
| الوصف: | e15691 Background: PRRT using 177Lu-DOTATATE was US FDA approved in Jan 2018, and real world data in the US is lacking. Methods: We retrospectively reviewed medical records of patients who began PRRT 03/14/18 - 10/01/18 at our institution. 177Lu-DOTATATE was administered at a dose of 200mCi over 20-30 min every 8 weeks for 4 doses. Infusion of arginine-lysine 25gm/25gm in 1-liter normal saline was given over 4 hours starting 30 min prior to treatment, in addition to intravenous palonosetron 0.25mg. Results: 51 patients received at least 1 of 4 doses and 40/51 were no longer on active therapy. 28/40 received all 4 doses and 12/40 discontinued treatment after < 4 doses. 25/40 were evaluable for response per RECIST v1.1. 16/25 (64%) had GI NET, 3/25 (12%) pancreatic NET, 4/25 (16%) atypical lung carcinoid, 1/25 (4%) multifocal NET, and 1/25 (4%) had paraganglioma. 28% had grade 1, 56% grade 2, and 8% (2/25) had grade 3 (Ki 67: 25% and 40%) NET. 12/25 (48%) had received ≥2 prior systemic therapies not including somatostatin analogs, and 10/25 (40%) had ≥1 prior liver-directed therapy. Median follow-up from date of last PRRT was 61.5 days. Objective response (partial response) rate was 16% (4/25; table). 18/25 (72%) had stable disease and 3/25 (12%) had progressive disease. Most adverse events (AEs) were grade 1-2 and included fatigue, nausea, abdominal pain, and cytopenias. ≥Grade 3 AEs requiring treatment discontinuation included symptomatic gastric outlet obstruction (2/51), small bowel obstruction (1/51), ischemic enteritis (1/51), confusion/bone pains (1/51), liver failure (1/51), and severe neutropenia (1/51). All patients with ≥grade 3 AEs had a high tumor burden at baseline. Conclusions: 177Lu-DOTATATE is an effective and safe treatment in advanced NET, and our results are consistent with NETTER 1 data.[Table: see text] |
| تدمد: | 1527-7755 0732-183X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::7348f23b717aadb11df69b3b22533f3e https://doi.org/10.1200/jco.2019.37.15_suppl.e15691 |
| رقم الأكسشن: | edsair.doi...........7348f23b717aadb11df69b3b22533f3e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|